National Semiconductor宣布推出一款可为先进的应用及通信处理器提供稳定供电的电源管理产品。这是该公司全新推出的多功能电源管理芯片系列的首款产品，具有可编程的灵活性，可为包括英特尔(Intel)的XScale处理器在内的采用ARM技术的...National Semiconductor宣布推出一款可为先进的应用及通信处理器提供稳定供电的电源管理产品。这是该公司全新推出的多功能电源管理芯片系列的首款产品，具有可编程的灵活性，可为包括英特尔(Intel)的XScale处理器在内的采用ARM技术的应用及通信处理器提供稳定的供电。展开更多
The molecular parameters of ArH＋ have been calculated with different quantum chemistry methods and basis sets.Based on the data from QCISD/Aug cc pVTZ ab initio calculation for different configurations of ArH＋ and t...The molecular parameters of ArH＋ have been calculated with different quantum chemistry methods and basis sets.Based on the data from QCISD/Aug cc pVTZ ab initio calculation for different configurations of ArH＋ and the experimental data,an accurate potential curve for ArH＋ has been constructed.The molecular properties,such as dissociation energy,equilibrium bond length,and vibrational energy levels,can be accurately reproduced.展开更多
Immunotherapy resistance remains a substantial barrier to improving treatment outcomes for patients with lung adenocarcinoma(LUAD).Identifying effective immunotherapy target is crucial for enhancing therapeutic effica...Immunotherapy resistance remains a substantial barrier to improving treatment outcomes for patients with lung adenocarcinoma(LUAD).Identifying effective immunotherapy target is crucial for enhancing therapeutic efficacy in LUAD.Through database analysis,we discovered that ADP ribosylhydrolase-like 1(ADPRHL1,ARH2)is associated with immunosuppression.In this study,we first demonstrated that the increased presence of ARH2-positive macrophages in LUAD tumors is associated with immunosuppression.Furthermore,ARH2 promotes M2 macrophage polarization and suppresses immune responses by regulating the FPR2/PI3K/AKT signaling pathway.Additionally,we found that artesunate(ART)can induce necroptosis in LUAD cells and activate antitumor immune responses.To translate these findings into a clinically viable therapeutic approach,we developed a pH/ROS-responsive nanosystem capable of co-delivering siARH2 and ART.This nanosystem effectively activated immune responses in both tumor cells and tumor-associated macrophages.Furthermore,the nanosystem demonstrated excellent in vivo safety,precise PD-L1 targeting,and responsiveness to ROS and pH variations.It considerably suppressed the malignant phenotype of tumor cells induced by macrophages and enhanced T-cell-mediated immune responses.Overall,targeting ARH2 in combination with ART represents a promising novel strategy for the treatment of LUAD.展开更多
文摘The molecular parameters of ArH＋ have been calculated with different quantum chemistry methods and basis sets.Based on the data from QCISD/Aug cc pVTZ ab initio calculation for different configurations of ArH＋ and the experimental data,an accurate potential curve for ArH＋ has been constructed.The molecular properties,such as dissociation energy,equilibrium bond length,and vibrational energy levels,can be accurately reproduced.
基金supported by the National Key Research and Development Program of China(No.2022YFC2403102)the Guangzhou Science and Technology Project(No.202201020097,2024A04J4492)+2 种基金the Affiliated Cancer Hospital&Institute of Guangzhou Medical University(No.2020-YZ-01)Wu Jieping Medical Foundation(No.320.6750.2023.19-9)the Medical Science and Technology Foundation of Guangdong Province(2021A1515010793).
文摘Immunotherapy resistance remains a substantial barrier to improving treatment outcomes for patients with lung adenocarcinoma(LUAD).Identifying effective immunotherapy target is crucial for enhancing therapeutic efficacy in LUAD.Through database analysis,we discovered that ADP ribosylhydrolase-like 1(ADPRHL1,ARH2)is associated with immunosuppression.In this study,we first demonstrated that the increased presence of ARH2-positive macrophages in LUAD tumors is associated with immunosuppression.Furthermore,ARH2 promotes M2 macrophage polarization and suppresses immune responses by regulating the FPR2/PI3K/AKT signaling pathway.Additionally,we found that artesunate(ART)can induce necroptosis in LUAD cells and activate antitumor immune responses.To translate these findings into a clinically viable therapeutic approach,we developed a pH/ROS-responsive nanosystem capable of co-delivering siARH2 and ART.This nanosystem effectively activated immune responses in both tumor cells and tumor-associated macrophages.Furthermore,the nanosystem demonstrated excellent in vivo safety,precise PD-L1 targeting,and responsiveness to ROS and pH variations.It considerably suppressed the malignant phenotype of tumor cells induced by macrophages and enhanced T-cell-mediated immune responses.Overall,targeting ARH2 in combination with ART represents a promising novel strategy for the treatment of LUAD.
